Ticker

Inhibrx Biosciences, Inc. (NASDAQ: INBX - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the company. The

SG Americas Securities LLC acquired a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,088 shares of the company's stock, valued at approximately $1,271,000. SG Americas Securities LLC owned approximately 0.11% of

Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and CollPlant Biotechnologies (NASDAQ: CLGN - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Risk and Volatility Inhibrx Biosciences has a

SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.

Dynamic Technology Lab Private Ltd bought a new position in Inhibrx Biosciences, Inc. (NASDAQ: INBX) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 7,388 shares of the company's stock, valued at approximately $249,000. Dynamic Technology Lab Private Ltd owned 0.05% of Inhibrx